Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA...
Saved in:
| Main Authors: | Peter Rohon, Jana Vondrakova, Anna Jonasova, Milena Holzerova, Marie Jarosova, Karel Indrak |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/369086 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature
by: Marianna Criscuolo, et al.
Published: (2011-01-01) -
5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature
by: Mariangela Greco, et al.
Published: (2011-03-01) -
Chronic myelomonocytic leukemia: A case report
by: Khevna Kansara, et al.
Published: (2024-10-01) -
Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01) -
Chronic Myelomonocytic Leukemia Associated With TAFRO Syndrome-Like Symptoms
by: Issam Drici-Tani, et al.
Published: (2024-05-01)